Abstract
Recent years have seen extensive growth in the understanding of the role(s) of the various PKC isozymes and novel receptors for the phorbol ester tumor promoters. The PKC family of serine-threonine kinases is an important regulator of signaling cascades that control cell proliferation and death, and therefore represent targets for cancer therapy. While past interests have focused on PKC-selective inhibitors, more recently, intensive research has been underway for selective activators and inhibitors for each individual PKC isozyme. In the past few years a large number of PKC activators and inhibitors with potential as anticancer agents have been developed. A number of these compounds are already in Phase II clinical testing. As a new generation of cancer chemotherapeutic agents are designed, developed and put through a series of rigorous clinical trials, we can anticipate achieving exquisite control over PKCmediated regulatory pathways, leading ultimately to a greater understanding of different cancers.
Current Pharmaceutical Design
Title: Protein Kinase C Isozymes, Novel Phorbol Ester Receptors and Cancer Chemotherapy
Volume: 7 Issue: 17
Author(s): Orla P. Barry and Marcelo G. Kazanietz
Affiliation:
Abstract: Recent years have seen extensive growth in the understanding of the role(s) of the various PKC isozymes and novel receptors for the phorbol ester tumor promoters. The PKC family of serine-threonine kinases is an important regulator of signaling cascades that control cell proliferation and death, and therefore represent targets for cancer therapy. While past interests have focused on PKC-selective inhibitors, more recently, intensive research has been underway for selective activators and inhibitors for each individual PKC isozyme. In the past few years a large number of PKC activators and inhibitors with potential as anticancer agents have been developed. A number of these compounds are already in Phase II clinical testing. As a new generation of cancer chemotherapeutic agents are designed, developed and put through a series of rigorous clinical trials, we can anticipate achieving exquisite control over PKCmediated regulatory pathways, leading ultimately to a greater understanding of different cancers.
Export Options
About this article
Cite this article as:
Orla P. Barry and Marcelo G. Kazanietz , Protein Kinase C Isozymes, Novel Phorbol Ester Receptors and Cancer Chemotherapy, Current Pharmaceutical Design 2001; 7 (17) . https://dx.doi.org/10.2174/1381612013397041
DOI https://dx.doi.org/10.2174/1381612013397041 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma
Anti-Cancer Agents in Medicinal Chemistry Regulatory Cross Talks of Bone Cells, Hematopoietic Stem Cells and the Nervous System Maintain Hematopoiesis
Inflammation & Allergy - Drug Targets (Discontinued) MicroRNAs and Targeted Therapies in Non-small Cell Lung Cancer: Minireview
Anti-Cancer Agents in Medicinal Chemistry Stem Cell-Mediated Gene Delivering for the Treatment of Cerebral Ischemia: Progress and Prospectives
Current Drug Targets Differential Expression of TOM34, AL1A1, PADI2 and KLRBA in NNK Induced Lung Cancer in Wistar Rats and their Implications
Current Cancer Drug Targets Heterocycle-thioacetic Acid Motif: A Privileged Molecular Scaffold with Potent, Broad-Ranging Pharmacological Activities
Current Pharmaceutical Design TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Preface
Recent Patents on Drug Delivery & Formulation Amantadine, Apomorphine and Zolpidem in the Treatment of Disorders of Consciousness
Current Pharmaceutical Design Biomedical Applications of Poly(Lactic Acid)
Recent Patents on Regenerative Medicine Acknowledgements to Reviewers
Clinical Cancer Drugs CAR T-cell Therapy: A New Era in Cancer Immunotherapy
Current Pharmaceutical Biotechnology Compartmentalized Platforms for Neuro-Pharmacological Research
Current Neuropharmacology Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research The Pursuit of Differentiated Ligands for the Glucocorticoid Receptor
Current Topics in Medicinal Chemistry PARP Inhibitors in Epithelial Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Targeted Pathways in Breast Cancer: Molecular and Protein Markers Guiding Therapeutic Decisions
Current Molecular Pharmacology Searching Drug-Like Anti-cancer Compound(s) Based on G-Quadruplex Ligands
Current Pharmaceutical Design Growth and Trophic Factors, pH and the Na+/H+ Exchanger in Alzheimers Disease, Other Neurodegenerative Diseases and Cancer: New Therapeutic Possibilities and Potential Dangers
Current Alzheimer Research Apoptosis-Induction is A Novel Therapeutic Strategy for Gastrointestinal and Liver Cancers
Current Gene Therapy